Patents Assigned to OREGON HEALTH & SCIENCE
  • Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
    Patent number: 11305015
    Abstract: CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: April 19, 2022
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • IMMUNOGENIC CONSTRUCTS, COMPOSITIONS, AND METHODS FOR INDUCING IMMUNE RESPONSE
    Publication number: 20220111039
    Abstract: Disclosed are immunogenic constructs including: a nanoparticle; a cationic polymer electrostatically bound to an exterior surface of the nanoparticle and a stabilizer bound to the cationic polymer or the exterior surface of the nanoparticle; and an antigen or antigen producing agent. Optionally, the constructs may include adjuvant and/or one or more functional oligonucleotide(s) (e.g., siRNA or pDNA). Also disclosed are methods of using the provided immunogenic constructs for co-delivering an adjuvant, antigen, and optionally siRNA to a cell, inducing immune response in a subject, and treating or preventing an infectious disease in a subject.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 14, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Sherif Reda, Moataz Reda, Worapol Ngamcherdtrakul, Ruijie Wang
  • Automated detection of shadow artifacts in optical coherence tomography angiography
    Patent number: 11302043
    Abstract: Disclosed herein are methods and systems for automated detection of shadow artifacts in optical coherence tomography (OCT) and/or OCT angiography (OCTA). The shadow detection includes applying a machine-learning algorithm to the OCT dataset and the OCTA dataset to detect one or more shadow artifacts in the sample. The machine-learning algorithm is trained with first training data from first training samples that include manufactured shadows and no perfusion defects and second training data from second training samples that include perfusion defects and no manufactured shadows. The shadow artifacts in the OCTA dataset and/or OCT dataset may be suppressed to generate a shadow-suppressed OCTA dataset and/or a shadow-suppressed OCT dataset, respectively. Other embodiments may be described and claimed.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: April 12, 2022
    Assignee: Oregon Health & Science University
    Inventors: Acner Camino, David Huang, Yali Jia
  • IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
    Publication number: 20220096628
    Abstract: Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.
    Type: Application
    Filed: December 13, 2021
    Publication date: March 31, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Amanda Lund, Worapol Ngamcherdtrakul, Moataz Reda
  • Device and method for blood volume measurement
    Patent number: 11284823
    Abstract: Disclosed are a method, device and system for determining total circulating blood volume (BV) using a minimally invasive technique.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: March 29, 2022
    Assignee: Oregon Health & Science University
    Inventors: Theodore Hobbs, Ravikant Samatham, Steven L. Jacques
  • THERAPEUTIC FACTOR XII ANTIBODY
    Publication number: 20220089776
    Abstract: Monoclonal antibodies that bind, such as specifically bind, blood protein factor XII (FXII) are described. The monoclonal antibodies (including antigen-binding fragments thereof) are capable of forming immune complexes with human FXII and inhibiting FXII activity, resulting in safe anti-inflammatory and anti-thrombotic effects.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 24, 2022
    Applicants: Oregon Health & Science University, Aronora, Inc.
    Inventors: Michael Wallisch, Andras Gruber, Erik I. Tucker, Christina U. Lorentz
  • THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20220071906
    Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.
    Type: Application
    Filed: November 23, 2021
    Publication date: March 10, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul
  • Recombinant HCMV and RHCMV vectors and uses thereof
    Patent number: 11266732
    Abstract: The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Oregon Health & Science University
    Inventors: Louis Picker, Jay A. Nelson, Klaus Frueh, Michael A. Jarvis, Scott G. Hansen
  • Detecting avascular areas using neural networks
    Patent number: 11263747
    Abstract: An example method includes generating, using a multi-scale block of a convolutional neural network (CNN), a first output image based on an optical coherence tomography (OCT) reflectance image of a retina and an OCT angiography (OCTA) image of the retina. The method further includes generating, using an encoder of the CNN, at least one second output image based on the first output image and generating, using a decoder of the CNN, a third output image based on the at least one second output image. An avascular map is generated based on the third output image. The avascular map indicates at least one avascular area of the retina depicted in the OCTA image.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 1, 2022
    Assignee: Oregon Health & Science University
    Inventors: Yali Jia, Yukun Guo
  • TRANSLATION OF IMAGES OF STAINED BIOLOGICAL MATERIAL
    Publication number: 20220058839
    Abstract: Techniques and systems for translating images of biological samples stained according to a first staining technique into images representing the biological samples stained according to a second staining technique. In various implementations, the first staining technique can include a histopathological staining technique and the second staining technique can include an immunofluorescence staining technique or an immunohistochemistry staining technique.
    Type: Application
    Filed: December 30, 2019
    Publication date: February 24, 2022
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Young Hwan Chang, Erik Burlingame, Geoffrey Schau, Joe W. Gray
  • NEAR-INFRARED NERVE-SPARING BENZO[C]PHENOXAZINE FLUOROPHORES
    Publication number: 20220041619
    Abstract: Provided are near-infrared nerve-sparing fluorescent compounds, compositions comprising them, and methods of their use in medical procedures.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 10, 2022
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Summer L. Gibbs, Lei G. Wang, Connor W. Barth
  • Immunotherapeutic constructs and methods of their use
    Patent number: 11235058
    Abstract: Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: February 1, 2022
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Amanda Lund, Worapol Ngamcherdtrakul, Moataz Reda
  • Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
    Patent number: 11224573
    Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: January 18, 2022
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul
  • Enteral feeding tube housing and fixation devices
    Patent number: 11213461
    Abstract: Enteric feeding tube housings configured to secure a feeding tube to the body are disclosed. The housing includes a disc having a hole configured to accommodate the feeding tube and two or more holes configured to accommodate fasteners. Also disclosed are enteric feeding tube housings that include a disc having a hole configured to accommodate the feeding tube and two or more holes configured to accommodate fasteners, and a plurality of fasteners. Also disclosed are surgical kits that include a housing, a plurality of fasteners, and a plurality of locking devices configured to adjustably secure the fasteners in the fastener receiving holes, and method of using the disclosed devices.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: January 4, 2022
    Assignee: Oregon Health & Science University
    Inventors: James P. Dolan, Younes Jahangiri Noudeh, Niloy Ghosh
  • Cross-linked polymer modified nanoparticles
    Patent number: 11207428
    Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 28, 2021
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe Gray
  • CROSS-LINKED POLYMER MODIFIED NANOPARTICLES
    Publication number: 20210393806
    Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
    Type: Application
    Filed: August 10, 2021
    Publication date: December 23, 2021
    Applicants: OREGON HEALTH & SCIENCE UNIVERSITY, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe William Gray
  • Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
    Patent number: 11197889
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: December 14, 2021
    Assignees: ABT Holding Company, Oregon Health & Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • METHODS FOR INCREASING YIELD OF SEQUENCING LIBRARIES
    Publication number: 20210380972
    Abstract: The present disclosure is concerned with compositions, methods, and kits for preparing a sequencing library. In one embodiment, methods include producing a library of target nucleic acids having the same adapter at each end and then switching the identity of one adapter to result in target nucleic acids flanked by distinct adapters.
    Type: Application
    Filed: June 10, 2021
    Publication date: December 9, 2021
    Applicants: Illumina, Inc., Illumina Cambridge Limited, Oregon Health & Science University
    Inventors: Andrew C. Adey, Ryan Mulqueen, Frank Steemers, Dmitry K Pokholok, Fan Zhang, Esther Musgrave-Brown
  • RECOMBINANT POLYPEPTIDES COMPRISING MODIFIED MHC CLASS II DRa1 DOMAINS AND METHODS OF USE
    Publication number: 20210380660
    Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.
    Type: Application
    Filed: October 4, 2019
    Publication date: December 9, 2021
    Applicants: Oregon Health & Science University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Roberto Meza-Romero, Arthur A. Vandenbark, Halina Offner
  • Real time monitoring and prediction of motion in MRI
    Patent number: 11181599
    Abstract: Methods, computer-readable storage devices, and systems are described for reducing movement of a patient undergoing a magnetic resonance imaging (MRI) scan by aligning MRI data, the method implemented on a Framewise Integrated Real-time MRI Monitoring (“FIRMM”) computing device including at least one processor in communication with at least one memory device. Aspects of the method comprise receiving a data frame from the MRI system, aligning the received data frame to a preceding data frame, calculating motion of a body part between the received data frame and the preceding data frame, calculating total frame displacement, and excluding data frames with a cutoff above a pre-identified threshold of the total frame displacement.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: November 23, 2021
    Assignees: Washington University, Oregon Health and Science University
    Inventors: Nico Dosenbach, Jonathan Koller, Andrew Van, Abraham Snyder, Amy Mirro, Damien Fair, Eric Earl, Rachel Klein, Oscar Miranda Dominguez, Anders Perrone